Glaukos shares have surged 45.7% since the end of May, outpacing the industry's 4% gain and the S&P 500's 0.9% decline. The rally was driven by investor enthusiasm following positive management commentary on iDose TR, despite proposed Medicare coverage restrictions that would limit the glaucoma therapy to patients who have failed both selective laser trabeculoplasty and two topical medications, restrict concurrent use with minimally invasive glaucoma surgery, and limit re-administration to once every two years. Management expressed confidence in securing modifications to these restrictions and is promoting iDose TR as a first-line treatment, while also highlighting the significant market opportunity and reaffirming 2026 and 2027 guidance. First-quarter iDose TR sales reached $54 million, with sequential growth expected in the second quarter. Additional support came from the encouraging launch of Epioxa, which has built a treatment network covering nearly 65% of the U.S. population and secured coverage for more than 100 million commercial lives, and a broad pipeline of 13 disclosed programs spanning glaucoma, corneal disorders, retinal diseases, and ocular surface therapies.
Veracyte Inc
West Pharmaceutical Services IncGlaukos CorpPositive management commentary on iDose TR and strong Q1 sales of $54M with sequential growth expected, despite Medicare restrictions.
Intuitive Surgical Inc